Research & Literature

The biology and management of systemic anaplastic large cell lymphoma.

Hapgood G, Savage KJ

Blood 2015; (126(1)):17-25 doi:10.1182/blood-2014-10-567461.

Recurrent Systemic Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma Presenting as a Breast Implant-Associated Lesion.

Zimmerman A, Locke FL, Emole J, et al.

Cancer control : journal of the Moffitt Cancer Center 2015; (22(3)):369-73 doi:10.1177/107327481502200317.

Coming of Age: Breast Implant-Associated Anaplastic Large Cell Lymphoma After 18 Years of Investigation.

Clemens MW, Miranda RN

Clinics in plastic surgery 2015; (42(4)):605-13.

[Expression of microRNA in ALK-negative anaplastic large cell lymphoma and CD30-positive peripheral T cell lymphoma, not otherwise specified].

Wang C, Chen X, Chen X, et al.

Zhonghua bing li xue za zhi = Chinese journal of pathology 2015; (44(8)):565-70.

ALK-negative anaplastic large-cell lymphoma.

Gaulard P, de Leval L

Blood 2016; (127(2)):175-7 doi:10.1182/blood-2015-11-676916.

Evaluation of peripheral lymphadenopathy with excisional biopsy: six-year experience.

Özkan EA, Göret CC, Özdemir ZT, et al.

International journal of clinical and experimental pathology 2015; (8(11)):15234-9.

Ultrasound-guided core needle biopsies for workup of lymphadenopathy and lymphoma.

Groneck L, Quaas A, Hallek M, et al.

European journal of haematology 2016; (97(4)):379-86 doi:10.1111/ejh.12742.

Skin involvement as the first manifestation of breast implant-associated anaplastic large cell lymphoma.

Alcalá R, Llombart B, Lavernia J, et al.

Journal of cutaneous pathology 2016; (43(7)):602-608 doi:10.1111/cup.12697.

Commentary on: Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Prince HM, Johnstone R

Aesthetic surgery journal 2016; (36(7)):782-3 doi:10.1093/asj/sjw065.

No TP63 rearrangements in a selected group of primary cutaneous CD30+ lymphoproliferative disorders with aggressive clinical course.

Schrader AM, Chung YY, Jansen PM, et al.

Blood 2016; (128(1)):141-3 doi:10.1182/blood-2016-02-694455.

Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma.

Blombery P, Thompson ER, Jones K, et al.

Haematologica 2016; (101(9)):e387-90 doi:10.3324/haematol.2016.146118.

Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis.

Kanazawa Y, Yamashita Y, Fujiwara M, et al.

Acta medica Okayama 2016; (70(6)):503-506 doi:10.18926/AMO/54815.

Primary cutaneous CD 30 (+) ALK (-) anaplastic large cell lymphoma with dermoscopic findings: a case report.

Uzuncakmak TK, Akdeniz N, Karadag AS, et al.

Dermatology practical & conceptual 2017; (7(1)):59-61 doi:10.5826/dpc.0701a12.

Specialized survivor clinic attendance increases adherence to cardiomyopathy screening guidelines in adult survivors of childhood cancer.

Marr KC, Agha M, Sutradhar R, et al.

Journal of cancer survivorship : research and practice 2017; (11(5)):614-623 doi:10.1007/s11764-017-0634-z.

Can Cutting-Needle Biopsy Be an Alternative to Excisional Biopsy in Lymph Node Pathologies?

Kiliçarslan A, Doğan M, Süngü N, et al.

Turk patoloji dergisi 2017; (1(1)):235-239 doi:10.5146/tjpath.2016.01393.

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.

Pro B, Advani R, Brice P, et al.

Blood 2017; (130(25)):2709-2717 doi:10.1182/blood-2017-05-780049.

Systemic and primary cutaneous anaplastic large cell lymphoma: Clinical features, morphological spectrum, and immunohistochemical profile.

Kwatra KS, Paul PAM, Calton N, et al.

South Asian journal of cancer 2017; (6(3)):129-131 doi:10.4103/2278-330X.214575.

Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma.

Iijima-Yamashita Y, Mori T, Nakazawa A, et al.

International journal of hematology 2018; (107(2)):244-250 doi:10.1007/s12185-017-2338-6.

ALCL: is it now a curable disease?

Zinzani PL

Blood 2017; (130(25)):2691-2692 doi:10.1182/blood-2017-10-811083.

Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Tsuyama N, Sakamoto K, Sakata S, et al.

Journal of clinical and experimental hematopathology : JCEH 2017; (57(3)):120-142 doi:10.3960/jslrt.17023.

Crizotinib induces apoptosis and gene expression changes in ALK+ anaplastic large cell lymphoma cell lines; brentuximab synergizes and doxorubicin antagonizes.

Hudson S, Wang D, Middleton F, et al.

Pediatric blood & cancer 2018; (65(8)):e27094 doi:10.1002/pbc.27094.

Breast implant-associated anaplastic large cell lymphoma: a review.

Quesada AE, Medeiros LJ, Clemens MW, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019; (32(2)):166-188 doi:10.1038/s41379-018-0134-3.

Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.

Locatelli F, Mauz-Koerholz C, Neville K, et al.

The Lancet. Haematology 2018; (5(10)):e450-e461 doi:10.1016/S2352-3026(18)30153-4.

Peripheral lymphadenopathy: role of excisional biopsy in differential diagnosis based on a five-year experience.

Campanelli M, Cabry F, Marasca R, Gelmini R

Minerva chirurgica 2019; (74(3)):218-223 doi:10.23736/S0026-4733.18.07752-0.

Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Rastogi P, Deva AK, Prince HM

Current hematologic malignancy reports 2018; (13(6)):516-524 doi:10.1007/s11899-018-0478-2.

Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy.

Moskowitz AJ

Hematology. American Society of Hematology. Education Program 2018; (2018(1)):207-212 doi:10.1182/asheducation-2018.1.207.

Breast implant-associated anaplastic large cell lymphoma: Clinical and imaging findings at a large US cancer center.

Dashevsky BZ, Gallagher KM, Grabenstetter A, et al.

The breast journal 2019; (25(1)):69-74 doi:10.1111/tbj.13161.

A practical cytological approach to the diagnosis of breast-implant associated anaplastic large cell lymphoma.

Barbé E, de Boer M, de Jong D

Cytopathology : official journal of the British Society for Clinical Cytology 2019; (30(4)):363-369 doi:10.1111/cyt.12678.

Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.

Torossian A, Broin N, Frentzel J, et al.

Haematologica 2019; (104(7)):1428-1439 doi:10.3324/haematol.2017.181966.

Achieving Reliable Diagnosis in Late Breast Implant Seromas: From Reactive to Anaplastic Large Cell Lymphoma.

Di Napoli A

Plastic and reconstructive surgery 2019; (143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma)):15S-22S doi:10.1097/PRS.0000000000005565.

Systemic, primary cutaneous, and breast implant-associated ALK-negative anaplastic large-cell lymphomas present similar biologic features despite distinct clinical behavior.

Gerbe A, Alame M, Dereure O, et al.

Virchows Archiv : an international journal of pathology 2019; (475(2)):163-174 doi:10.1007/s00428-019-02570-4.

Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma.

Wang X, Wu J, Zhang M

Hematology (Amsterdam, Netherlands) 2019; (24(1)):440-445 doi:10.1080/16078454.2019.1613290.

A Prospective Approach to Inform and Treat 1340 Patients at Risk for BIA-ALCL.

Roberts JM, Carr LW, Jones A, et al.

Plastic and reconstructive surgery 2019; (144(1)):46-54 doi:10.1097/PRS.0000000000005703.

Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma.

Ishizawa K, Yanai T

Advances in therapy 2019; (36(10)):2679-2696 doi:10.1007/s12325-019-01046-w.

[Current standard in diagnostic and therapy of peripheral T-cell lymphoma].

Hopfinger G, Staber P

Deutsche medizinische Wochenschrift (1946) 2019; (144(20)):1400-1404 doi:10.1055/a-0597-7606.

Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma.

Turner SD, Inghirami G, Miranda RN, Kadin ME

The American journal of pathology 2020; (190(1)):2-10 doi:10.1016/j.ajpath.2019.09.005.

Quantification of minimal disseminated disease by quantitative polymerase chain reaction and digital polymerase chain reaction for NPM-ALK as a prognostic factor in children with anaplastic large cell lymphoma.

Damm-Welk C, Kutscher N, Zimmermann M, et al.

Haematologica 2020; (105(8)):2141-2149 doi:10.3324/haematol.2019.232314.

Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin.

Nakai R, Fukuhara S, Maeshima AM, et al.

Clinical case reports 2019; (7(12)):2500-2504 doi:10.1002/ccr3.2543.

Peripheral neuropathy in hematologic malignancies - Past, present and future.

Li T, Timmins HC, Lazarus HM, Park SB

Blood reviews 2020; (43()):100653 doi:10.1016/j.blre.2020.100653.

Adherence to Surveillance for Second Malignant Neoplasms and Cardiac Dysfunction in Childhood Cancer Survivors: A Childhood Cancer Survivor Study.

Yan AP, Chen Y, Henderson TO, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020; (38(15)):1711-1722 doi:10.1200/JCO.19.01825.

Recombinant expression, characterization, and quantification in human cancer cell lines of the Anaplastic Large-Cell Lymphoma-characteristic NPM-ALK fusion protein.

Kourentzi K, Crum M, Patil U, et al.

Scientific reports 2020; (10(1)):5078 doi:10.1038/s41598-020-61936-w.

Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Current Understanding and Recommendations for Management.

St Cyr TL, Pockaj BA, Northfelt DW, et al.

Plastic surgery (Oakville, Ont.) 2020; (28(2)):117-126 doi:10.1177/2292550320925906.

Relaxation versus exercise for improved quality of life in lymphoma survivors-a randomised controlled trial.

Hathiramani S, Pettengell R, Moir H, Younis A

Journal of cancer survivorship : research and practice 2021; (15(3)):470-480 doi:10.1007/s11764-020-00941-4.

A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia

Ma W, Zhao J, Zhang L

Turkish journal of haematology : official journal of Turkish Society of Haematology 2021; (38(1)):87-89 doi:10.4274/tjh.galenos.2020.2020.0521.

STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma.

Lobello C, Tichy B, Bystry V, et al.

Leukemia 2021; (35(5)):1500-1505 doi:10.1038/s41375-020-01093-1.

Successful combination of crizotinib and hematopoietic stem cell transplantation in relapsed ALK-positive ALCL.

Sun X, Fang X, Jiang Y

Indian journal of cancer 2021; (58(1)):108-111 doi:10.4103/ijc.IJC_961_19.

Crizotinib Resistance Mediated by Autophagy Is Higher in the Stem-Like Cell Subset in ALK-Positive Anaplastic Large Cell Lymphoma, and This Effect Is MYC-Dependent.

Shang C, Hassan B, Haque M, et al.

Cancers 2021; (13(2)) doi:10.3390/cancers13020181.

Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells.

Kuravi S, Cheng J, Fangman G, et al.

Molecular cancer research : MCR 2021; (19(5)):913-920 doi:10.1158/1541-7786.MCR-20-0738.

Treatment of Relapsed and Refractory ALK-Positive Anaplastic Large Cell Lymphoma With ALK-Specific Tyrosine Kinase Inhibitor in Children: A Case Series.

Shen D, Song H, Zhang J, et al.

Journal of pediatric hematology/oncology 2022; (44(1)):e1-e4 doi:10.1097/MPH.0000000000002137.

Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.

Lowe EJ, Reilly AF, Lim MS, et al.

Blood 2021; (137(26)):3595-3603 doi:10.1182/blood.2020009806.

Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease?

Rigaud C, Abbas R, Grand D, et al.

Pediatric blood & cancer 2021; (68(6)):e28982 doi:10.1002/pbc.28982.

A Meta-Ethnography of the Experiences of Adults with Lymphoma During Acute and Chronic Survivorship.

Vena JA, Copel LC

Seminars in oncology nursing 2021; (37(2)):151142 doi:10.1016/j.soncn.2021.151142.

Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors: A case report.

Saito S, Tashiro H, Sumiyoshi R, et al.

Medicine 2021; (100(15)):e25576 doi:10.1097/MD.0000000000025576.

ALK-Negative Anaplastic Large Cell Lymphoma (ALCL): Prognostic Implications of Molecular Subtyping and JAK-STAT Pathway.

Parkhi M, Bal A, Das A, et al.

Applied immunohistochemistry & molecular morphology : AIMM 2021; (29(9)):648-656 doi:10.1097/PAI.0000000000000936.

Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.

Nizamuddin I, Galvez C, Pro B

Seminars in hematology 2021; (58(2)):85-94 doi:10.1053/j.seminhematol.2021.02.006.

Minimal Disease Monitoring in Pediatric Non-Hodgkin's Lymphoma: Current Clinical Application and Future Challenges.

Mussolin L, Damm-Welk C, Pillon M, Woessmann W

Cancers 2021; (13(8)) doi:10.3390/cancers13081907.

Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.

Martinez-Calle N, Kirkwood AA, Lamb M, et al.

Advances in therapy 2021; (38(7)):3789-3802 doi:10.1007/s12325-021-01764-0.

Comparison of Allogeneic Stem Cell Transplant and Autologous Stem Cell Transplant in Refractory or Relapsed Peripheral T-Cell Lymphoma: A Systematic Review and Meta-analysis.

Du J, Yu D, Han X, et al.

JAMA network open 2021; (4(5)):e219807 doi:10.1001/jamanetworkopen.2021.9807.

Updates in the Treatment of Peripheral T-Cell Lymphomas.

Saleh K, Michot JM, Ribrag V

Journal of experimental pharmacology 2021; (13()):577-591 doi:10.2147/JEP.S262344.

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.

Subbiah V, Kuravi S, Ganguly S, et al.

ESMO open 2021; (6(4)):100172 doi:10.1016/j.esmoop.2021.100172.

Breast Implant-associated Anaplastic Large Cell Lymphoma Diagnosis 6 Years After Implant Removal: A Case Report.

Barnea Y, Clemens MW, Madah E, et al.

Annals of plastic surgery 2022; (88(2)):157-161 doi:10.1097/SAP.0000000000002945.

Prevalence and severity of scanxiety in people with advanced cancers: a multicentre survey.

Bui KT, Kiely BE, Dhillon HM, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; (30(1)):511-519 doi:10.1007/s00520-021-06454-9.

ALK-Negative Anaplastic Large Cell Lymphoma: Current Concepts and Molecular Pathogenesis of a Heterogeneous Group of Large T-Cell Lymphomas.

Pina-Oviedo S, Ortiz-Hidalgo C, Carballo-Zarate AA, Zarate-Osorno A

Cancers 2021; (13(18)) doi:10.3390/cancers13184667.

Prognostic Role of Minimal Disseminated Disease and NOTCH1/FBXW7 Mutational Status in Children with Lymphoblastic Lymphoma: The AIEOP Experience.

Lovisa F, Gallingani I, Varotto E, et al.

Diagnostics (Basel, Switzerland) 2021; (11(9)) doi:10.3390/diagnostics11091594.

Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma.

Khanlari M, Li S, Miranda RN, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2022; (35(3)):412-418 doi:10.1038/s41379-021-00944-1.

Use of flow cytometry and cytology to differentiate breast implant-associated anaplastic large cell lymphoma from reactive seromas in Brazilian patients.

De Azambuja AP, Gevert F, Oliveira RM, et al.

Cytometry. Part B, Clinical cytometry 2022; (102(4)):312-316 doi:10.1002/cyto.b.22040.

Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy.

Velasco R, Domingo-Domenech E, Sureda A

Cancers 2021; (13(23)) doi:10.3390/cancers13236125.

Diagnostic and prognostic implications of tumor expression of the GATA-3 gene in nodal peripheral T-cell lymphoma (nPTCL): Retrospective data from a Latin American cohort.

de Pádua Covas Lage LA, Brito CV, Levy D, et al.

Leukemia research 2022; (114()):106794 doi:10.1016/j.leukres.2022.106794.

Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment.

Zhang XR, Chien PN, Nam SY, Heo CY

Cancers 2022; (14(7)) doi:10.3390/cancers14071650.

Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus.

Gru AA, Lim MS, Dogan A, et al.

Archives of pathology & laboratory medicine 2023; (147(1)):79-86 doi:10.5858/arpa.2021-0270-OA.

Breast Implant-Associated Anaplastic Large Cell Lymphoma: Two Distinct Clinical Presentations.

Miranda P, Moita F, Vargas Moniz J, Rodrigues Dos Santos C

Acta medica portuguesa 2022; (35(11)):835-839 doi:10.20344/amp.16578.

An Unusual Case of Breast Implant-Associated Anaplastic Large Cell Lymphoma.

Premji S, Barbieri A, Roth C, et al.

Case reports in hematology 2022; (2022()):4700787 doi:10.1155/2022/4700787.

The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.

Zhang S, Gu C, Huang L, et al.

Scientific reports 2022; (12(1)):10488 doi:10.1038/s41598-022-14523-0.

A challenging case of ALK-negative anaplastic large cell lymphoma in a 12-year-old boy: A rare case report from Syria.

Abdul Rahman SA, Loutfi K, Turk T, et al.

Annals of medicine and surgery (2012) 2022; (79()):104085 doi:10.1016/j.amsu.2022.104085.

Management of Peripheral T-cell Lymphomas and the Role of Transplant.

Foley NC, Mehta-Shah N

Current oncology reports 2022; (24(11)):1489-1499 doi:10.1007/s11912-022-01310-3.

Primary Leptomeningeal Lymphoma: Clinicopathologic Features of 2 Rare Phenotypes.

Vizcaino MA, Giannini C, King RL, et al.

Journal of neuropathology and experimental neurology 2022; (81(12)):1002-1007 doi:10.1093/jnen/nlac084.

JAK/STAT3 Signaling Activation Related to Distinct Clinicopathologic Features in Systemic ALK - Anaplastic Large Cell Lymphomas : New Insights into Their Heterogeneity.

Wang JC, Zhong LH, Lin WQ, et al.

The American journal of surgical pathology 2023; (47(1)):55-64 doi:10.1097/PAS.0000000000001995.

Differential diagnosis and identification of prognostic markers for peripheral T-cell lymphoma subtypes based on flow cytometry immunophenotype profiles.

Pu Q, Qiao J, Liu Y, et al.

Frontiers in immunology 2022; (13()):1008695 doi:10.3389/fimmu.2022.1008695.

Clinical recommendations for diagnosis and treatment according to current updated knowledge on BIA-ALCL.

Longo B, Di Napoli A, Curigliano G, et al.

Breast (Edinburgh, Scotland) 2022; (66()):332-341 doi:10.1016/j.breast.2022.11.009.

Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1.

Lowe EJ, Reilly AF, Lim MS, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(11)):2043-2053 doi:10.1200/JCO.22.00272.

Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

Derry-Vick HM, Heathcote LC, Glesby N, et al.

Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

Refractory Anaplastic Large Cell Lymphoma Rescued by the Combination of the Second-Generation ALK Inhibitor Brigatinib, High-dose Chemotherapy and Allogeneic Stem Cell Transplantation: A Case Report and Review of the Literature.

Caddeo G, Tecchio C, Chinello M, et al.

Clinical hematology international 2023; (5(2-3)):130-138 doi:10.1007/s44228-023-00038-6.

Frontline Management of Nodal Peripheral T-Cell Lymphomas.

Ngu HS, Savage KJ

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2023; (43()):e390334 doi:10.1200/EDBK_390334.

Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.

Agrusa JE, Egress ER, Lowe EJ

Frontiers in immunology 2023; (14()):1203471 doi:10.3389/fimmu.2023.1203471.

Clinical profile and outcome of children with anaplastic large cell lymphoma treated with short-course chemotherapy - ten years experience from a tertiary care center in a LMIC.

Trivedi M, Thankamony P, Nair M, et al.

Pediatric hematology and oncology 2023; (40(5)):485-496 doi:10.1080/08880018.2023.2212710.

Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review.

Noguchi K, Ikawa Y

Cancers 2023; (15(24)) doi:10.3390/cancers15245733.

Our Experience in Diagnosing and Treating Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).

Shoham G, Haran O, Singolda R, et al.

Journal of clinical medicine 2024; (13(2)) doi:10.3390/jcm13020366.

Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.

Liu W, Wu J, Ming X, et al.

Frontiers in immunology 2024; (15()):1346001 doi:10.3389/fimmu.2024.1346001.

How I Follow Hodgkin Lymphoma in First Complete (Metabolic) Remission?

Milunović V

Medicina (Kaunas, Lithuania) 2024; (60(2)) doi:10.3390/medicina60020344.

18 F-FDG PET/CT in Synovial Anaplastic Large Cell Lymphoma.

Chiu KL, Chow TK, Ma WH, Ma KM

Clinical nuclear medicine 2024; (49(7)):666-668 doi:10.1097/RLU.0000000000005140.

Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy.

Matthys A, Bardel B, Le Bras F, et al.

European journal of neurology 2024; (31(7)):e16285 doi:10.1111/ene.16285.

Breast Implant-Associated Anaplastic Large Cell Lymphoma: Where Hematology and Plastic Surgery Meet.

Joks MM, Czernikiewicz K, Mazurkiewicz Ł, et al.

Clinical lymphoma, myeloma & leukemia 2024; (24(9)):e293-e300 doi:10.1016/j.clml.2024.05.008.

Anthracycline-induced hypertension in pediatric cancer survivors: unveiling the long-term cardiovascular risks.

Taghdiri A

The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology 2024; (76(1)):71 doi:10.1186/s43044-024-00506-1.

Role of ALK Inhibitors in Anaplastic Large Cell Lymphoma-Experience from an Indian Center.

Indhuja MV, Kesana S, Mehra N, et al.

South Asian journal of cancer 2024; (13(2)):121-125 doi:10.1055/s-0042-1758353.

[ALK-positive anaplastic large cell lymphoma of paranasal sinuses: two cases report and literature review].

Abramov DS, Fedorova AS, Tuzova EA, et al.

Arkhiv patologii 2024; (86(4)):42-47 doi:10.17116/patol20248604142.

Beyond surgery: the proper role and delivery of radiation therapy in the local-regional management of BIA-ALCL.

Gunther JR, Iyer SP, Hunt KK, et al.

Case reports in plastic surgery & hand surgery 2024; (11(1)):2389172 doi:10.1080/23320885.2024.2389172.

Pharmacovigilance study of the association between peripheral neuropathy and antibody-drug conjugates using the FDA adverse event reporting system.

Chen Y, Ren X, Dai Y, Wang Y

Scientific reports 2024; (14(1)):21386 doi:10.1038/s41598-024-71977-0.

Systemic ALK-negative anaplastic large cell lymphoma: Insights into morphologic, immunophenotypic, genetic and molecular characteristics.

Xie W, Medeiros LJ, Fan G, et al.

Human pathology 2025; (156()):105671 doi:10.1016/j.humpath.2024.105671.

Fine Needle Aspirate Flow Cytometry's Ancillary Utility in Diagnosing Non-Hodgkin Lymphoma in the Head and Neck.

Bandargal S, Florianova L, Dmitrienko S, et al.

Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale 2024; (53()):19160216241296127 doi:10.1177/19160216241296127.

Anaplastic lymphoma kinase-negative primary systemic anaplastic large cell lymphoma mimicking a ruptured epidermal cyst of the scalp: a case report and literature review.

Ahn IY, Bae TH, Kang SH, et al.

Archives of craniofacial surgery 2024; (25(6)):298-302 doi:10.7181/acfs.2024.00262.

Comparison of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future Research Agenda.

Valcarcel B, Savage KJ, Link BK, et al.

JCO oncology practice 2025; (21(6)):801-812 doi:10.1200/OP.24.00364.

BV and beyond: how to incorporate novel agents into PTCL management.

Nizamuddin IA, Mehta-Shah N

Hematology. American Society of Hematology. Education Program 2024; (2024(1)):54-61 doi:10.1182/hematology.2024000530.

Cognitive behavioral stress management effects on cancer-related distress and neuroendocrine signaling in breast cancer: differential effects by neighborhood disadvantage.

Ream M, Plotke R, Taub CJ, et al.

Breast cancer research and treatment 2025; (211(1)):161-172 doi:10.1007/s10549-025-07631-8.

The Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers: A Review.

DeVine A, Landier W, Hudson MM, et al.

JAMA oncology 2025; (11(5)):544-553 doi:10.1001/jamaoncol.2024.6812.

Treatment and outcome of breast implant-associated anaplastic large cell lymphoma: a population-based cohort study in the Netherlands.

Meeuwes FO, Brink M, van der Poel MWM, et al.

Leukemia & lymphoma 2025; (66(11)):2064-2070 doi:10.1080/10428194.2025.2530167.

Advances and updates in pediatric anaplastic large cell lymphoma.

Marks LJ, Lowe E, Kamdar K

Blood advances 2025; (9(19)):4870-4880 doi:10.1182/bloodadvances.2025015935.

Primary Cutaneous Anaplastic Large Cell Lymphoma with Locoregional Lymph Node Involvement: Challenges in Diagnosis and Clinical Management.

Garcia-Garcia M, Tardin Cardoso AL, Val IS, et al.

The American Journal of dermatopathology 2025; (47(11)):866-870 doi:10.1097/DAD.0000000000003103.

Primary Gingival Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma in a Young Boy.

Lutz CM, Bruneau J, Molina TJ, Ejeil AL

Cureus 2025; (17(8)):e89217 doi:10.7759/cureus.89217.

Rosai-Dorfman disease mimicking IgG4-related disease.

Cetin O, Yetisir S, Akpinar TS, et al.

Wiener medizinische Wochenschrift (1946) 2026; (176(1-2)):60-63 doi:10.1007/s10354-025-01110-x.

Recent advances and future perspectives in frontline treatment of peripheral T-cell lymphoma.

Shirouchi Y, Yamauchi N, Maruyama D

Japanese journal of clinical oncology 2026; (56(1)):24-32 doi:10.1093/jjco/hyaf158.

Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

Shah MS, Memon JA, Malik U, et al.

Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

Comparative analysis on efficacy of lymph node sampling through whole node excision versus core needle biopsy: focusing on diagnostic yield for interpretation.

Singh N, Mishra S, Balasubramanian P, et al.

Journal of hematopathology 2025; (18(1)):46 doi:10.1007/s12308-025-00662-6.

CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas.

Stein H, Falini B

American journal of hematology 2026; (101(1)):110-128 doi:10.1002/ajh.70107.

Emerging therapeutic strategies for CD30-positive lymphomas.

Boretti A

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2026; (28(5)):1501-1515 doi:10.1007/s12094-025-04151-1.

Gene expression profiling reveals 2 overarching types of ALCL with distinct targetable biology: an LLMPP study.

Feldman AL, Dasari S, Rimsza LM, et al.

Blood 2026; (147(11)):1199-1214 doi:10.1182/blood.2024027700.

ALK-positive anaplastic large cell lymphoma presenting as an endobronchial polyp in a pediatric patient.

Venkatappa HA, Nargund A, Okaly GVP, et al.

International cancer conference journal 2025; (14(4)):513-517 doi:10.1007/s13691-025-00805-7.

Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma Presenting as an Axillary Breast Abscess in a Young Woman: A Case Report.

Amamnkwah D, Ibrahim F

Cureus 2025; (17(12)):e99911 doi:10.7759/cureus.99911.

Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK-Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan.

Mori T, Kada A, Osumi T, et al.

Cancer science 2026; (117(3)):777-786 doi:10.1111/cas.70308.

Fine-Needle Aspiration Biopsy Diagnosis of T-Cell Non-Hodgkin Lymphomas: Morphologic Features, Ancillary Testing, and Diagnostic Pitfalls.

Cozzolino I, Zeppa P, Medeiros LJ

Acta cytologica 2026; 1-22 doi:10.1159/000550789.